Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 3/20 | 0.47 |
| ▸ | MCHR2 | Q969V1 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 3/20 | 0.42 |
| ▸ | TOP2A | P11388 | 1/20 | 0.42 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4779482 | 1.00 | MCHR1 (0.47) | MCHR1MCHR2KCNH2HTR2AHTR2C | |
| SCHEMBL6359649 | 0.92 | HTR2A (0.54) | MCHR1MCHR2HTR2AHTR2CHTR2B | |
| SCHEMBL5636335 | 0.89 | HTR2A (0.53) | HTR2AHTR2CHTR2BATMCTSK | |
| SCHEMBL5050630 | 0.89 | HTR2A (0.53) | HTR2AHTR2CHTR2BATMCTSK | |
| SCHEMBL14274480 | 0.84 | PREP (0.43) | MCHR1MCHR2MAOAATMCTSK | |
| SCHEMBL3545732 | 0.82 | HTR2A (0.51) | MCHR1MCHR2KCNH2HTR2AHTR2C | |
| SCHEMBL5783787 | 0.82 | HTR2A (0.51) | MCHR1MCHR2KCNH2HTR2AHTR2C | |
| SCHEMBL3545731 | 0.82 | HTR2A (0.51) | MCHR1MCHR2KCNH2HTR2AHTR2C | |
| SCHEMBL4793492 | 0.80 | HDAC8 (0.43) | MCHR1MCHR2MAOAATMCTSK | |
| SCHEMBL14274481 | 0.79 | CTSK (0.40) | MCHR1MCHR2MAOAATMCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080033184-A1 | INTERMEDIATES AND METHODS FOR SEROTONERGIC AGONIST SYNTHESIS | ALCON MANUFACTURING, LTD. (US) | 2008-02-07 | — | — | US | claimed |
| US-20080033184-A1 | INTERMEDIATES AND METHODS FOR SEROTONERGIC AGONIST SYNTHESIS | ALCON MANUFACTURING, LTD. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080033184-A1 | INTERMEDIATES AND METHODS FOR SEROTONERGIC AGONIST SYNTHESIS | ALCON MANUFACTURING, LTD. (US) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033184-A1 | INTERMEDIATES AND METHODS FOR SEROTONERGIC AGONIST SYNTHESIS | HTR3B, HTR3A, HTR4 | MCHR1 181/4885MCHR2 366/4885KCNH2 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.